CDKN2AIPNL Inhibitors
Inhibitors targeting CDKN2AIPNL operate through diverse biochemical mechanisms to diminish the activity of this protein. Agents that hinder cyclin-dependent kinases, specifically CDK4/6, contribute to cell cycle arrest, which in turn indirectly restrains CDKN2AIPNL activity by interrupting its cell cycle-related processes. Similarly, chemicals that inhibit histone deacetylases lead to hyperacetylation of histones, thereby altering chromatin architecture and potentially limiting CDKN2AIPNL expression by obstructing transcription factor access to DNA. In addition, proteasome inhibitors, by preventing the breakdown of ubiquitinated proteins, could cause an accumulation of cell cycle regulators that interfere with the function of CDKN2AIPNL. Furthermore, inhibitors targeting the PI3K/AKT/mTOR and mTOR signaling pathways, which are essential for cellular survival and proliferation, could lead to a decrease in CDKN2AIPNL activity, as this protein is associated with these pathways.
Compounds that interfere with fundamental cellular functions can act as indirect CDKN2AIPNL inhibitors. For instance, antimetabolites that disrupt DNA synthesis may reduce CDKN2AIPNL's replication-dependent functions by curtailing cell proliferation. MDM2 antagonists, which promote p53 stability and consequently induce cell cycle arrest and apoptosis, can influence CDKN2AIPNL functionality due to the interplay between the p53 pathway and CDKN2AIPNL's regulatory roles. Topoisomerase inhibitors that impair DNA replication and repair mechanisms, and chemicals that block the MAPK/ERK pathway involved in cell differentiation and growth, are also capable of reducing CDKN2AIPNL's activity. Additionally, histone deacetylase inhibitors that affect transcriptional regulation and tyrosine kinase inhibitors that target angiogenic processes may also indirectly limit CDKN2AIPNL activity by disrupting the protein's involvement in chromatin accessibility and cellular response to hypoxia, respectively.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Cyclin-dependent kinase inhibitor that specifically interferes with CDK4/6, leading to a halt in cell cycle progression which can indirectly inhibit CDKN2AIPNL by preventing its associated cell cycle-dependent processes. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Histone deacetylase inhibitor that causes hyperacetylation of histones, this can disrupt the chromatin structure and indirectly inhibit transcription factors from accessing the DNA, potentially reducing CDKN2AIPNL expression. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
Proteasome inhibitor that prevents the degradation of ubiquitinated proteins, potentially causing an accumulation of regulatory proteins that could interfere with CDKN2AIPNL's function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
PI3K inhibitor that blocks the PI3K/AKT/mTOR signaling pathway, which is involved in cell survival and proliferation, thereby potentially decreasing the functional activity of CDKN2AIPNL which is interconnected with these survival pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
mTOR inhibitor that disrupts the mTOR signaling pathway, which is critical for cell cycle progression and growth, potentially leading to reduced activity of CDKN2AIPNL linked to these processes. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $36.00 $149.00 | 11 | |
Antimetabolite that interferes with DNA synthesis, thereby indirectly inhibiting the replication-dependent functions of CDKN2AIPNL by reducing the proliferation of cells. | ||||||
Nutlin-3 | 548472-68-0 | sc-45061 sc-45061A sc-45061B | 1 mg 5 mg 25 mg | $56.00 $212.00 $764.00 | 24 | |
MDM2 antagonist that stabilizes p53, leading to cell cycle arrest and apoptosis; this stabilization may indirectly affect CDKN2AIPNL function due to the interaction between p53 pathway and CDKN2AIPNL's associated processes. | ||||||
Mitoxantrone | 65271-80-9 | sc-207888 | 100 mg | $279.00 | 8 | |
Topoisomerase II inhibitor that disrupts DNA replication and repair, potentially reducing the functional activity of CDKN2AIPNL by interfering with its involvement in cell cycle checkpoints and DNA repair mechanisms. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Proteasome inhibitor that can lead to cell cycle arrest by stabilizing proteins that inhibit cell division, potentially downregulating CDKN2AIPNL activity as it is involved in cell cycle regulation. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
MEK inhibitor that blocks the MAPK/ERK pathway, which is involved in cell growth and differentiation, potentially decreasing the functional activity of CDKN2AIPNL which may be regulated by this pathway. | ||||||